Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01527136 · ClinicalTrials.gov registry record · Phase 1
Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT01527136 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 25 participants.
The verdict
NCT01527136, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of entolimod in treating patients with locally advanced or metastatic solid tumors that cannot be removed by surgery. Biological therapies, such as entolimod, may stimulate the immune system in different ways and stop tumor cells from growing.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG entolimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01527136
The ClinicalTrials.gov registry entry for NCT01527136 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01527136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01527136 about?
NCT01527136 is a clinical study titled "Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery". This phase I trial studies the side effects and best dose of entolimod in treating patients with locally advanced or metastatic solid tumors that cannot be removed by surgery. Biological therapies, such as entolimod, may stimulate the immune system in different ways and stop tumor cells from growing...
What is the current status of trial NCT01527136?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2012-01. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01527136?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), entolimod (DRUG).
Who is sponsoring clinical trial NCT01527136?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.